A Nanodroplet Processor for Advanced Microencapsulated Drug Formulations, Phase I

The objective of this proposal is to provide a demonstration of a nanodroplet synthesis of multifunctional liposomes for drug delivery based on immiscible microfluidics processing. In this initial study, the functionality of the liposomes will include (1) the surface functionalized particles for targeting specific cells and (2) the protected packaging of protein therapeutics that may be released upon specific binding of the liposome to a targeted cell. This goal will be accomplished using nanodroplet technology that exploits the properties of immiscible fluids to transform continuous fluid streams into highly monodispersed, isolated droplets with tight control of droplet size and generation rate. The nanoparticles are formed at room temperature with low pressure and shear forces to prevent the denaturation of protein drugs, which will be important for the treatment of major diseases such as heart disease and cancer. Since cells rapidly uptake nanoparticles with sizes less than 500 nm, the major objective for this proposal is demonstrate highly monodisperse particles in this regime. Furthermore, we anticipate that producing such particles in a microgravity environment will lead to an improved fundamental understanding of droplet formation itself and to the production of homogeneously distributed therapeutics in a perfectly spherical nano-particle.

This is a mature technology (TRL 7+) — the realistic path in is usually NASA's Technology Transfer Program: licensing an existing NASA patent, or a Space Act Agreement to use NASA facilities/expertise directly. NASA also runs a startup licensing program with no upfront fee for companies formed to commercialize a specific NASA technology.

None of these are guaranteed paths for this specific project — TechPort itself doesn't have an "apply" button. Reaching out to the contact(s) above with a specific question is usually the fastest way to find out what's actually open.